Biotech - Spark Newswire

1 minute read

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer

June 4, 10:04 AM

Surface Oncology (NASDAQ:SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC:RHHBY) to evaluate former’s SRF388, anti-IL-27 antibody, in combination…

RHHBF

1 minute read

Coherus, Junshi Toripalimab-Chemo Combo Beat Chemo Alone in Late-Stage Nose & Throat Cancer Trial

By Vandana Singh

June 4, 10:01 AM

Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ:CHRS) have announced positive results from the pivotal Phase 3 JUPITER-02 trial evaluating toripalimab…

CHRS

5 minute read

The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact

By Shanthi Rexaline

June 4, 9:39 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 3)

ALLO

1 minute read

FDA
News

NGM Biopharmaceuticals Publishes Clinical Trial Titled ‘Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies’ To ClinicalTrials.Gov

By Benzinga Newsdesk

June 4, 9:34 AM

https://clinicaltrials.gov/ct2/show/NCT04913337

NGM

1 minute read

Nanobiotix’s Nanoparticle Technology Shows Tumor-Killing Effect in Early-Stage Head & Neck Cancer

By Vandana Singh

June 4, 9:34 AM

Nanobiotix (NASDAQ:NBTX), ahead of the 2021 Annual Meeting of the American Society for Clinical Oncology meeting, has said that…

NBTX

5 minute read

Alkermes Says Presents New Data On Nemvaleukin Alfa At 2021 ASCO Meeting

By Benzinga Newsdesk

June 4, 9:19 AM

Alkermes plc (NASDAQ:ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investigational engineered interleukin-2 (IL-2)

ALKS

3 minute read

FDA
News

Puma Biotech Highlights Presentation Of Data From Phase 3 ExteNET Trial In Early Stage HER2-Positive Breast Cancer Patients At American Society Of Clinical Oncology

By Benzinga Newsdesk

June 4, 9:17 AM

Results show improved outcomes in overall survival in patients with HER2-positive early stage breast cancer who received ≥ 11 months of treatment with neratinib LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc.

PBYI

3 minute read

FDA
News

Puma Biotech Highlights Presentation Of Data Comparing Findings From Phase 2 CONTROL Trial With Neratinib Arm Of Phase 3 ExteNET Trial At American Society of Clinical Oncology

By Benzinga Newsdesk

June 4, 9:14 AM

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, presented results at the virtual 2021 ASCO Annual Meeting comparing the diarrhea mitigation strategies investigated in the Phase II CONTROL trial with

PBYI

3 minute read

Agenus Says Co’s Presentations At ASCO 2021 ‘Demonstrate Differentiated Activity of Balstilimab and Provide Clinical Update on AGEN2373’

By Benzinga Newsdesk

June 4, 9:14 AM

Agenus (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections,

AGEN

6 minute read

BeiGene Presents Clinical Data From 2 Phase 2 Trials Of Pamiparib At 2021 ASCO Meeting

By Benzinga Newsdesk

June 4, 9:09 AM

Pamiparib, a potent and selective PARP1 and PARP2 inhibitor, demonstrated meaningful and durable efficacy in patients with advanced HER2-negative breast cancer Pamiparib showed numerically higher progression-free

BGNE